Verastem, Inc.
VSTMHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframePart of the healthcare sector, Verastem, Inc. (VSTM) is listed under Biotechnology. Valued at $742.6M, VSTM is a small-cap name in its sector. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAPK signaling pathway that is commonly activated in various cancers; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Market Cap
$742.6M
Beta
0.32
P/E (TTM)
—
P/E (Fwd)
-10.93
EPS (TTM)
$-2.44
EPS (Fwd)
$-0.75
ROE
-471.2%
ROA
-49.6%
Cash
$136.4M
Total Debt
$84.3M
Free CF
-$103.4M
52W Change
-17.3%
Annual Financials
Cash vs Debt
Where VSTM stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, VSTM finished 44.24% above its 150-day moving average ($5.56) and 28.32% above its 200-day moving average ($6.25). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VSTM overbought or oversold?
At the September 3, 2026 close, VSTM's RSI(14) was 71.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $136.4M in cash comfortably exceeding the $84.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$103.4M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -471.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $2.6M (2022) to $30.9M (2025), reflecting a 1091% increase over the period.
The relatively low beta of 0.32 suggests VSTM is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing VSTM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.